Pfizer
2Q Revenues: $13.5 billion (+4%)
2Q Earnings: $3.9 billion (+20%)
YTD Revenues: $26.4 billion (+3%)
YTD Earnings: $7.4 billion (20%)
Comments: Innovative Health sales were $8.3 billion in the quarter, up 8%. Growth from key brands included Eliquis, Ibrance and Xeljanz globally, Prevnar 13/Prevenar 13 primarily in emerging markets and the U.S., as well as Xtandi in the U.S. Operational revenue growth for Eliquis, Ibrance, Xeljanz and Xtandi was 42%, 19%, 37% and 21%, respectively. Essential Health sales were $5.2 billion, down 1% with a 12% operational decline in the Legacy Established Products portfolio in developed markets; a 17% operational decline in the Sterile Injectable Pharmaceuticals portfolio in developed markets, primarily due to continued legacy Hospira product shortages in the U.S.; 10% operational growth in emerging markets, reflecting growth across all portfolios; and 44% operational growth from Biosimilars, primarily from Inflectra in certain channels in the U.S. as well as in developed Europe.